David Sinclair on the Longevity Pill, Age Reversal Timelines, and Updated Protocols | EP #249

Summary

• Sinclair says Life Biosciences is recruiting patients for an imminent glaucoma trial that could provide a fast human readout on epigenetic age reversal. ER-100 delivers three Yamanaka factors—OSK—to the eye, building on restored vision in mice and monkeys; he says six weeks may be enough for an observable result because “it’s going to be fairly obvious if someone can see again or not.”
• The investable thesis is broader than blindness: Sinclair presents OSK as a potentially tissue-agnostic rejuvenation platform. Preclinical work across the field reports benefits in brain aging, memory, Alzheimer’s models, motor neurons, immunity, muscle, kidney, liver, skin and joints. Diamandis’s test is exacting: “A true longevity therapeutic…would work throughout the entire body.”
• Delivery economics separate the first-generation asset from the mass-market endgame. Diamandis cites traditional AAV therapies at roughly $500,000-$2 million per treatment; Sinclair hopes to treat millions of glaucoma patients and says he hopes the cost will fall substantially. His lab’s AI-screened three-molecule cocktail is intended to become one drug, ultimately “like metformin”—potentially affordable worldwide.
• Sinclair’s timeline is aggressive but explicitly conditional: 2026 “may be” the year age reversal is demonstrated in humans. He now considers success within our lifetimes highly likely because multiple teams and substantial capital are pursuing it, even if his own program hits setbacks. Sinclair compares the transition to the Wright brothers; Diamandis says, “Once you can fly, everything changes.”
• He rejects a known biological lifespan ceiling without claiming immortality. Humans have reached 122, and Sinclair says lifespans of hundreds of years already occur in the animal world; he sees no biological or physics-based rule imposing a fixed limit. Nevertheless, he says, “I’m not saying…we can live forever” and admits he does not know how humans might reach hundreds or thousands of years.
• Private funding has materially accelerated Sinclair’s research cadence after government support in the millions was cut. Diamandis says Friends of Sinclair Lab generated roughly $6 million in annual private support, allowing projects to start within weeks instead of facing a grant process with a stated 10% success rate. Sinclair says he had previously spent “half my time writing grants.”
• Sinclair’s personal protocol centers on glucose control, vascular risk and consistency—not a claim of product endorsement. He reports resveratrol with fat or protein, NMN, and cycling between 1 gram daily metformin and berberine. He has also added nattokinase; after discussing the dose, he gives 10,000 units and says trials took a year. Separately, Diamandis says data he calls “damning” led him to stop daily alcohol, after which his inflammation biomarkers fell within a month; Sinclair says he now drinks much less.

Deep dive

1. OSK has reached the threshold of human testing

• Sinclair says patients are being recruited for Life Biosciences’ imminent glaucoma study of ER-100, a drug candidate from his lab whose work was first published in 2020 on the cover of Nature under “Turning Back Time.” Because treatment lasts about six weeks and vision is measurable, he thinks doctors may learn relatively quickly whether it works in humans.

• He credits student Onecheng Lu with finding OSK, three Yamanaka factors intended to reset age without erasing cellular identity or causing cancer. The distinction is existential: using all the factors kills mice within two days, and turning a person into “a giant lump of stem cells…would not be good.”

• The eye was not Sinclair’s preferred starting point—he initially favored liver because curing blindness looked harder. Yet the approach restored vision in mice and monkeys, while a localized eye trial offered regulators a more cautious first step than injecting an untested reprogramming therapy throughout the body.

2. The endgame moves from local gene therapy to a systemic pill

• Sinclair says preclinical work across the field reports brain-age reversal, improved memory in old animals and Alzheimer’s models, and benefits involving motor neurons, immunity, muscle, kidney, liver and skin. Another group’s recent joint study, he says, suggests regrowth of cartilage and even bone.

• Diamandis’s challenge—worth preserving—is that success in one cell type is not yet true longevity medicine: “A true longevity therapeutic…would work throughout the entire body.” Sinclair agrees, but says systemic delivery will require technology such as lipid nanoparticles or a chemical small molecule after tissue-by-tissue safety is established.

• Diamandis estimates conventional AAV treatments at roughly $500,000-$2 million; Sinclair hopes to bring the price down and stresses his ambition to treat millions of glaucoma patients. The present candidate is “2017 technology,” while the lab has spent the intervening years pursuing something that could ultimately be made for a few cents per pill.

• AI screens billions of molecules in silico, while visual machine learning tests whether skin cells from 92-year-olds can be reversed back to a 20-year-old state. Sinclair reports a three-molecule proof of concept and hopes to test it in humans within months as part of the XPRIZE competition; FDA combination requirements mean a commercial drug would ideally be one molecule.

3. A positive human readout would reset the perceived lifespan ceiling

• Sinclair’s categorical position is that “there is no law that says we have to age.” Humans have reached 122, and he says lifespans of hundreds of years already occur in the animal world; he sees no biological or physics-based reason for a hard ceiling, while conceding that he does not yet know how people could reach hundreds or thousands of years.

• The change in his confidence comes from what he describes as cells’ “backup copy”: reprogramming does not merely make them behave better but makes them young and keeps them young. His team rebooted mouse eyes multiple times; the animals eventually died of old age, “but they had really good eyesight.”

• He carefully rejects the claim that humans can live forever, yet compares the field to the Wright brothers’ first flight. Twenty years ago he did not know whether reversal would arrive within our lifetimes; now multiple teams and substantial funding make success seem likely, and he says “it may be 2026” when humans learn that age reversal is possible. Diamandis then frames that test as learning whether humanity can fly.

4. Private patronage is compressing scientific timelines

• After what Diamandis describes as a battle between the White House and Harvard cut government funding in the millions, he launched Friends of Sinclair Lab with an initial $50,000. He says supporters subsequently supplied about $6 million in annual private support; Sinclair now considers the lab better positioned than before the cuts.

• Their indictment of grants is operational: scientists may wait years for a roughly 10% chance of funding, while Sinclair spent “half my time writing grants.” When a student on dialysis disclosed that she needed a kidney, member Brett Blundy asked how fast they could address it and immediately funded the project—turning an idea into work within weeks. The community has about 70 members and may be capped.

5. The updated protocol prioritizes glucose, plaque and lower stress

• Sinclair frames the regimen as personal, not product promotion. His 15-year staples remain resveratrol—taken with olive oil, yogurt or another fatty or protein-rich food for absorption—and NMN; he also cycles between 1 gram daily metformin and berberine, both used to lower glucose.

• Diamandis adds that Fountain Life’s member data show hemoglobin A1C correlating with heart disease more strongly than HDL, LDL or Lp(a). Sinclair’s practical instruction is correspondingly plain: watch glucose, pasta, carbohydrates and especially processed carbohydrates.

• A newer addition is nattokinase. Sinclair says large trials of 1,000-plus people showed plaque reversal, that the trials took a year, and—after asking Serena—gives 10,000 units as the dose; he initially says the amount may be at least 8,000. He plans another carotid ultrasound to check his own IMT and prefers ultrasound over CT radiation, which he says his lab finds accelerates aging.

• Sinclair is now mostly vegan and says he drinks much less alcohol. Diamandis says data showing that even one daily glass correlates with a smaller brain led him to abandon nightly cheese and red wine; his inflammation biomarkers fell within a month. Sinclair also credits Serena with teaching him meditation, says reduced tension improved his sleep and appearance, and emphasizes blood pressure, cholesterol, blood sugar and social connection because “loneliness will kill you.”